Global Plasma Fractionation Market Size was $33.71 Billion in 2023

Global Plasma Fractionation Market Overview

According to Global Market Monitor, the global plasma fractionation market size was $33.71 billion in 2023 with a CAGR of 6.18% from 2023 to 2028. Plasma fractionation is fractionating whole blood or separating it into parts. This is typically done by centrifuging the blood.

Market Drivers

Plasma contains abundant proteins, many of which can be used as biomarkers, indicating the presence of certain diseases in an individual. Currently, 2D Electrophoresis is the primary method for discovering and detecting biomarkers in plasma. This involves the separation of plasma proteins on a gel by exploiting differences in their size. Potential disease biomarkers may be present in plasma at very low concentrations, so, plasma samples must undergo preparation procedures for accurate results to be obtained using 2D Electrophoresis. These preparation procedures aim to remove contaminants that may interfere with the detection of biomarkers, solubilize the proteins to undergo 2D Electrophoresis analysis, and prepare plasma with minimal loss of low-concentration proteins, but optimal removal of high-abundance proteins.

Key Players

CSL Behring is one of the major players operating in the plasma fractionation market, holding a share of 20.23% in 2023. CSL Behring LLC, a biopharmaceutical company, engages in the research, development, manufacture, and marketing of protein-based therapies for the treatment of serious and rare conditions worldwide. It offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing biotherapies. The company also operates a plasma collection network.

Company Name	CSL Behring
Website	www.cslbehring.com
Established Time	2000
Plants Distribution	North America
Sales Region	Worldwide
Competitors	Grifols, Takeda, Octapharma